Empagliflozin is a synthetic sodium-glucose cotransporter-2 (SGLT2) inhibitor used as an active pharmaceutical ingredient in medicines for type 2 diabetes and other approved cardiovascular and renal indications. It works by reducing glucose reabsorption in the kidneys, thereby increasing urinary glucose excretion.
Empagliflozin is a white to yellowish, non-hygroscopic powder. It is supplied as the free-base drug substance and is chemically distinct from combination-product ingredients such as metformin hydrochloride. The exact identity, purity profile and quality requirements should be verified through the approved product specification and batch-specific Certificate of Analysis (COA).
Empagliflozin is used in the manufacture of approved pharmaceutical products for conditions in which SGLT2 inhibition is indicated. It is also used in pharmaceutical formulation development, analytical research and quality-control activities.
Potential pharmaceutical manufacturing and development applications include:
Empagliflozin may also be used in approved combination products. Each combination must comply with its own applicable formulation and regulatory requirements.
Empagliflozin selectively inhibits sodium-glucose cotransporter-2 (SGLT2), the principal transporter responsible for reabsorbing filtered glucose in the kidneys. Inhibition of SGLT2 reduces renal glucose reabsorption and increases urinary glucose excretion.
This mechanism lowers blood glucose through a pathway that is independent of insulin secretion. Empagliflozin also affects renal sodium handling, which contributes to its broader pharmacological effects.
Empagliflozin is a white to yellowish, non-hygroscopic powder. It is very slightly soluble in water, sparingly soluble in methanol, slightly soluble in ethanol and acetonitrile, soluble in 50% acetonitrile-water and practically insoluble in toluene.
The compound is not described as a hydrate or solvate in the cited product information. Its solid-state characteristics and any applicable polymorphic controls should be confirmed against the approved API specification.
Empagliflozin API quality assessment may include:
The applicable test methods and numerical acceptance limits must be taken from the current approved specification and batch COA. IP compliance should only be claimed when the applicable official monograph or regulatory documentation confirms it.
Empagliflozin should be packed in suitable, tightly closed containers that protect the material from contamination and inappropriate environmental exposure. Storage temperature, light protection and retest period should follow the approved stability data and product-specific storage instructions.
Handle Empagliflozin API in an appropriate pharmaceutical manufacturing environment. Use suitable personal protective equipment, dust-control measures and documented material-handling procedures. Avoid inhalation, ingestion, direct contact and uncontrolled environmental release. Consult the current Safety Data Sheet for hazard classification, first-aid guidance and disposal requirements.
This page concerns bulk API procurement and pharmaceutical manufacturing, not patient-use or dosing instructions.
What is Empagliflozin?
Empagliflozin is an SGLT2 inhibitor used as an active ingredient in approved pharmaceutical products.
What is the CAS number of Empagliflozin?
Its CAS number is 864070-44-0.
What is the molecular formula of Empagliflozin?
Its molecular formula is C23H27ClO7.
What is the molecular weight of Empagliflozin?
Its molecular weight is approximately 450.91 g/mol.
What is the appearance of Empagliflozin API?
It is described as a white to yellowish, non-hygroscopic powder.
What is the mechanism of action of Empagliflozin?
It inhibits SGLT2 in the kidneys, reducing glucose reabsorption and increasing urinary glucose excretion.
Which tests are relevant for Empagliflozin API?
Typical quality tests include identification, assay, related substances, residual solvents, water content or loss on drying and other tests included in the approved specification.
Is Empagliflozin IP compliant?
IP compliance must be established against the current official Indian Pharmacopoeia monograph or applicable approved regulatory specification. Do not infer compliance from the product name alone.
For Empagliflozin API procurement, request the current product specification, batch COA, analytical method details, regulatory documentation, packaging configuration and storage requirements. Include your required quantity and intended pharmaceutical manufacturing application in your enquiry.
| Parameter | Specification |
|---|---|
| Appearance | White to yellowish |
| Identification | IR and HPLC complaint |
| Assay (HPLC) | 97.0–103.0% |
| Loss on Drying | NMT 0.5% |
| Residue on Ignition | NMT 0.1% |
| Heavy Metals | NMT 10 ppm |
| Solubility | Very slightly soluble in water |